Methoxetamine: Difference between revisions
>Dextromethorphan mxe is extinct |
>Unity Wording and grammatics. Content standardization. |
||
Line 2: | Line 2: | ||
{{SubstanceBox/Methoxetamine}} | {{SubstanceBox/Methoxetamine}} | ||
'''3-MeO-2'-Oxo-PCE''' (commonly known as '''Methoxetamine''', '''MXE''', '''Mexxy''', among others) is a [[psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class that produces [[ | '''3-MeO-2'-Oxo-PCE''' (commonly known as '''Methoxetamine''', '''MXE''', '''Mexxy''', among others) is a [[psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class that produces [[ketamine|ketamine-like]] [[dissociative]] effects when [[administered]]. It is structurally related to [[ketamine]], [[PCE]], and [[3-MeO-PCP]].<ref>MXE Binding profile | http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/methoxetamine2012?view=Binary</ref> | ||
<ref>MXE Binding profile | http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/methoxetamine2012?view=Binary</ref> | |||
MXE was originally developed through the use of intelligent drug design, as a potential treatment for [https://en.wikipedia.org/wiki/Phantom_pain Phantom Limb Syndrome] among other ailments.<ref>Interview with a ketamine chemist | https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2</ref> | |||
MXE had | MXE had no documented history of human usage and was first identified in November 2010 by the European Monitoring Centre for Drugs and Drug Addiction, which monitors the Internet for new psychoactive substances within the European Union. By July 2011, they had identified 58 websites selling the compound at the cost of 145–195 euros for 10 grams.<ref>Online sales of new psychoactive substances/‘legal highs’ | http://www.emcdda.europa.eu/attachements.cfm/att_143801_EN_SnapshotSummary.pdf</ref> Once highly popular, it is now thought to be extinct on the online [[research chemical]] market due to the global ban of the drug. | ||
Limited data exists about the pharmacological properties, metabolism, and toxicity of MXE in humans, and it has a limited history of human use. It is highly advised to use [[harm reduction practices]] if using this substance. | Limited data exists about the pharmacological properties, metabolism, and toxicity of MXE in humans, and it has a limited history of human use. It is highly advised to use [[harm reduction practices]] if using this substance. | ||
Line 31: | Line 28: | ||
|{{effects/physical| | |{{effects/physical| | ||
*'''[[Effect::Spontaneous | *'''[[Effect::Sedation]]''' | ||
*'''[[Effect::Spontaneous bodily sensations]]''' - The MXE "body high" can be described as a sharp, pleasurable tingling sensation which is location specific to the hands, feet, and head. | |||
*'''[[Effect::Perception of bodily lightness]]''' - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate doses by making the body feel light and effortless to move. | *'''[[Effect::Perception of bodily lightness]]''' - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate doses by making the body feel light and effortless to move. | ||
*'''[[Effect::Motor control loss]]''' - A loss of gross and fine motor control alongside balance and coordination is prevalent within MXE and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless experienced) in the case of falling over and injuring oneself. | *'''[[Effect::Motor control loss]]''' - A loss of gross and fine motor control alongside balance and coordination is prevalent within MXE and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless experienced) in the case of falling over and injuring oneself. | ||
Line 175: | Line 172: | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Research chemical]] | *[[Research chemical]] | ||
*[[ | *[[Dissociatives]] | ||
*[[ | *[[Arylcyclohexylamines]] | ||
*[[Ketamine]] | *[[Ketamine]] | ||
*[[3-MeO-PCP]] | *[[3-MeO-PCP]] | ||
Line 185: | Line 181: | ||
*[https://www.erowid.org/chemicals/methoxetamine/ MXE (Erowid Vault)] | *[https://www.erowid.org/chemicals/methoxetamine/ MXE (Erowid Vault)] | ||
*[https://isomerdesign.com/PiHKAL/explore.php?id=689 MXE (Isomer Design)] | *[https://isomerdesign.com/PiHKAL/explore.php?id=689 MXE (Isomer Design)] | ||
=== | ===Discussion=== | ||
*[http://www.bluelight.org/vb/threads/524290-The-Big-amp-Dandy-Methoxetamine(2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone)-Thread The Big & Dandy Methoxetamine Thread (Bluelight)] | *[http://www.bluelight.org/vb/threads/524290-The-Big-amp-Dandy-Methoxetamine(2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone)-Thread The Big & Dandy Methoxetamine Thread (Bluelight)] | ||